DOCSLIB.ORG

Not for Distribution to Retail Clients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Not for Distribution to Retail Clients PAGE 1 Not for distribution to Retail Clients Week ending August 27, 2021 COMPANY COMMENTARY SHARE PRICE PERFORMANCE Canadian Cannabis Producers Canadian Extraction Companies Canadian Cannabis Retailers 48North announced that it has obtained a final court order from the Ontario Canadian Other Other North American Cannabis Companies Supreme Court of Justice approving the plan of arrangement, pursuant to which International Cannabis Companies Ancillary Cannabis Companies Indices HEXO will acquire all of 48North’s issued and outstanding common shares YTD Since Last Week Acreage announced the appointment of Bryan Murray, former Global Avant Brands 519% Aleafia 15% Operations Lead for Public Affairs at Pfizer, as its Executive Vice President Decibel 321% Auxly 12% of Government Relations Cannara 113% Avant Brands 10% OrganiGram 95% Sundial 9% AFC Gamma announced that it has provided a credit facility of US$19.75 mm to Tilray 62% OrganiGram 9% DMA Holdings MA, a single-state Massachusetts operator Sundial 61% Aurora 6% TGOD 13% Village Farms 6% Aleafia Health announced the closing of a C$10 mm senior secured term credit Auxly 10% HEXO 5% facility Entourage Health (4%) Tilray 5% Village Farms (6%) Rubicon Organics 4% Aurora and Ethypharm announced that they have delivered their initial shipment Cronos (7%) Cronos 4% of cannabis to the French medical cannabis pilot program, set to begin serving Aurora (14%) TGOD 2% patients in the coming weeks Delta 9 (19%) Canopy 1% Aleafia (28%) Cannara -- Avant Brands announced that its joint venture, 3PL Ventures, has been issued Canopy (31%) Entourage Health -- Standard Cultivation, Standard Processing and Medical Sales Licenses; Avant HEXO (34%) Delta 9 (3%) Brands also announced that it has been added to the Global X Cannabis ETF Rubicon Organics (38%) Flowr (5%) (NASDAQ: POTX) Flowr (68%) Decibel (16%) Valens 88% Nextleaf -- Avicanna announced that its RHO Phyto and Pura Earth branded topicals have Nextleaf 18% MediPharm Labs (1%) attained initial listing and commenced sales in the Canadian province of Alberta; Radient (24%) Valens (2%) MediPharm Labs (38%) Radient (7%) Avicanna also announced that, through its majority-owned Colombian subsidiary High Tide 135% Fire & Flower 3% Santa Marta Golden Hemp, it has completed its first commercial export of 20 kg Nova 26% Nova 1% of high CBD full spectrum psychoactive cannabis extracts to Brazil Fire & Flower 8% High Tide (2%) RIV Capital 30% Neptune 15% Ayr Wellness announced the opening of Liberty Health Sciences Boynton Avicanna (17%) Willow Biosciences 4% Beach, its 40th operating dispensary in Florida; Ayr Wellness also announced that Namaste (20%) Avicanna -- its Board has authorized, effective immediately, the repurchase of up to 5% of its Willow Biosciences (36%) Namaste -- Neptune (55%) RIV Capital (2%) Subordinate Voting Shares over the next 12 months pursuant to a normal course MedMen 122% C21 11% issuer bid; Ayr Wellness also announced the launch of its Origyn Extracts MariMed 103% cbdMD 7% premium concentrates line in Arizona, its first national brand portfolio to launch in Harvest Health 36% Curaleaf 6% Arizona Ascend Wellness 31% Planet 13 4% Gage 30% Cansortium 4% Canopy Growth subsidiary Tokyo Smoke announced a partnership with Green Thumb 22% Green Thumb 4% Cadillac Fairview Partners to open multiple mall store locations 4Front 20% Columbia Care 3% Verano 14% 4Front 2% Cansortium announced that its wholly-owned subsidiary, Fluent by Ayr Wellness 2% MariMed 2% Cansortium, received approval from the Florida Department of Health to Cresco 0% Cresco 2% Curaleaf 0% Trulieve 1% commence operation of a new 43,000 sq. ft. greenhouse cultivation facility in Cansortium (1%) TerrAscend 1% Homestead, Florida and the 40,000 sq. ft. greenhouse expansion at its Goodness Growth (4%) Ascend Wellness -- Sweetwater, FL cultivation facility; Cansortium also announced FQ2 ’21 revenue Acreage (9%) Harvest Health (1%) of US$16.5 mm (improved 9% q/q) and adj. EBITDA of US$5.2 mm (improved Planet 13 (11%) Goodness Growth (1%) Trulieve (15%) The Parent Company (2%) 18% q/q) Jushi (21%) Jushi (2%) Charlotte's Web (26%) Verano Cresco Labs is reportedly investing US$40 mm to expand a cannabis cultivation (4%) TerrAscend (28%) Gage (5%) and processing facility in Ohio, which will nearly triple the size of its facility in cbdMD (28%) Acreage (7%) Yellow Springs Columbia Care (33%) Ayr Wellness (8%) C21 (44%) Charlotte's Web (8%) Cronos Group and Ginkgo Bioworks announced the achievement of the first The Parent Company (63%) MedMen (10%) target productivity equity milestone in their partnership to produce eight cultured Flora Growth 87% Little Green Pharma 4% cannabinoids Little Green Pharma 27% IM Cannabis 3% Intercure 22% MedLab 3% Curaleaf announced the opening of a Curaleaf dispensary in Bordentown, New Clever Leaves 11% Intercure 2% Jersey, marking its 109th dispensary nationwide; Curaleaf also announced the MedLab (23%) Cann Group -- launch of its Select brand in New Jersey, expanding the Select brand’s reach to Khiron (25%) Clever Leaves (2%) Panaxia 19 states (42%) Panaxia (3%) PharmaCielo (43%) PharmaCielo (5%) Decibel announced a bought deal for 45.0 mm units (share + half a warrant @ Cann Group (51%) Khiron (12%) C$0.40) at a price of C$0.29 per unit for gross proceeds of ~C$13.05 mm IM Cannabis (53%) Flora Growth (26%) TILT 59% Greenlane 18% Delta 9 announced the grand opening of its thirteenth Delta 9 Cannabis retail IIPR 31% Hydrofarm 14% store, and tenth cannabis store in the Province of Manitoba Zynerba 26% Zynerba 11% AFC Gamma 12% GrowGeneration 6% Weedmaps 5% AFC Gamma 6% Hydrofarm (6%) IIPR 3% GrowGeneration (23%) TILT 2% Greenlane (34%) Weedmaps 1% Source: Public filings, Bloomberg, FactSet S&P 500 20% MJ ETF 4% Note: Includes select cannabis companies. Share price performance based on share S&P / TSX 18% NASDAQ Composite 3% price appreciation only. NASDAQ Composite 17% S&P 500 2% Dow Jones Industrial 16% Dow Jones Industrial 1% MJ ETF 16% S&P / TSX 1% PAGE 2 COMPANY COMMENTARY (CONT’D) Fire & Flower and its wholly-owned subsidiary, Hifyre, announced the proposed acquisition of PotGuide for total consideration of ~US$8.5 mm, consisting of US$4.0 mm in cash and ~6.0 mm common shares Flora Growth announced that it has closed the previously announced €2.0 mm investment in Hoshi International, while also increasing its fully-diluted ownership in Hoshi through a securities swap Gage Growth announced FQ2 ’21 revenue of US$26.4 mm (improved 50% q/q) and adj. EBITDA loss of US$1.9 mm (improved 50% q/q); Gage Growth also announced that it entered into an amended and new licensing agreement with Cookies extending their partnership from 2024 to 2026 Greenlane and KushCo both announced that they have received stockholders approved for the proposed merger of both companies Greenway announced that it has entered into an agreement with Agro-Green Natural Products, whereby Greenway will supply 200 kg of cannabis biomass per month as inputs to support the Shelter Wildfire Preroll brand across Canada and through Shelter Market GrowGeneration announced the acquisition of Hoagtech Hydroponics, a hydroponic equipment and indoor gardening store, serving the Bellingham, Washington area, marking its 59th hydroponic garden center nationwide; GrowGeneration announced its acquisition of Commercial Grow Supply, a hydroponic superstore located in Santa Clarita, California, with annual revenues approaching US$10 mm, bringing the number of GrowGen locations in California to 22 Halo announced that it has entered into a definitive agreement to acquire Food Concepts, the master tenant of a ~55,000 sq. ft. indoor cannabis cultivation, processing, and wholesaling facility in Portland, Oregon operated under the Pistil Point name and the related licenses issued by the Oregon Liquor Control Commission (OLCC) and other operating assets owned by the entities doing business as Pistil Point; Halo will acquire Food Concepts for US$8.2 mm, payable in ~258.2 mm Halo common shares, and will acquire the OLCC licenses and Pistil Points other assets for US$4.0 mm, payable in ~125.9 mm Halo common shares Harvest One announced that its Dream Water brand launched a new line for sleep gummies in the American market, which is expected to hit its distributors and retailers in September HEXO announced that the previously announced transfer of its stock exchange listing to the Nasdaq from the NYSE is complete; HEXO also announced the closing of its previously announced underwritten public offering for gross proceeds of ~US$144.8 mm at a price of US$2.95 per unit (share + half warrant @ US$3.45), including 1.6 mm units sold pursuant to the partial exercise of the over-allotment option; HEXO also announced that its shareholders showed overwhelming support for the previously announced acquisition of Redecan; HEXO also announced appointment of Guillaume Jouet as its Chief People & Culture Officer High Tide announced that all outstanding convertible debentures originally issued by Meta Growth have now been converted into common shares of High Tide, more than one year prior to maturity iAnthus announced that it is in receipt of a purported notice from the Lenders and the Consenting Debenture Holders to unilaterally extend the outside date for closing the recapitalization transaction beyond the existing outside date of August 31, 2021 Indiva announced FQ2 ’21 net revenue of C$9.1 mm (improved 46% q/q) and adj. EBITDA of C$0.5 mm (improved 204% q/q) Jane Technologies announced
Load more

Recommended publications
  • When It Comes to Cannabis Potency?
    Testimony Should Canada “Start Low and Go Slow” When It Comes to Cannabis Potency? CT-­492 Testimony presented before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada on May 7, 2018. C O R P O R A T I O N For more information on this publication, visit www.rand.org/pubs/testimonies/CT492.html Testimonies RAND testimonies record testimony presented or submitted by RAND associates to federal, state, or local legislative committees; government-appointed commissions and panels; and private review and oversight bodies. Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation RA® is a registered trademark. Limited Print andElectronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html. www.rand.org Should Canada “Start Low and Go Slow” When It Comes to Cannabis Potency? Testimony of Beau Kilmer1 The RAND Corporation2 Before the Standing Committee on Social Affairs, Science, and Technology Senate of Canada May 7, 2018 hairperson Eggleton, Deputy Chairperson Petitclerc, Deputy Chairperson Seidman, and other distinguished members of the Standing Committee on Social Affairs, Science, and C Technology, thank you very much for the opportunity to testify before you today.
    [Show full text]
  • Clearing the Smoke on Cannabis Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals
    7 Clearing the Smoke on Cannabis Edible Cannabis Products, Cannabis Extracts and Cannabis Topicals Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Key Points • Edible cannabis products, cannabis extracts and cannabis topicals have unique health and safety risks that are not inherent to dried cannabis. • High-potency cannabis extracts increase the risk of over-intoxication more This is the seventh in a series of than dried cannabis. Although limited, the available evidence indicates that reports that reviews the effects of frequent use of these products is associated with problematic cannabis use, cannabis use on various aspects of cannabis use disorder and mental health disorders. human functioning and development. • Edible cannabis products can increase the risk of over-consumption and Other reports in this series address subsequent over-intoxication and impairment. Because when unpackaged they look like ordinary food and beverage products, edible cannabis products the link between regular cannabis use also increase the risk of unintentional ingestion, especially by children. and mental health, regular cannabis • Research on cannabis topicals, including the use of topical and transdermal use and cognitive functioning, maternal cannabidiol products, is limited. There is, however, growing interest among cannabis use during pregnancy, dermatologists and consumers in these cannabis products. cannabis use and driving, respiratory • The health impacts associated with long-term use of edible cannabis and cardiovascular effects of smoking products, cannabis extracts and cannabis topicals are not known. cannabis, and the medical use of • Public education efforts will play an important role in mitigating the harms cannabis and cannabinoids. This series associated with new cannabis products.
    [Show full text]
  • Nurturing New Growth Canada Gets Ready for Cannabis 2.0 Table of Contents
    Nurturing new growth Canada gets ready for Cannabis 2.0 Table of contents Introduction 1 Cannabis 2.0: Canadian survey insights 4 Perspectives on Cannabis 2.0 22 The way forward: Thriving in a Cannabis 2.0 world 30 Remain bold 32 Nurturing new growth | Canada gets ready for Cannabis 2.0 | Introduction Introduction ll eyes remain on Canada as it prepares for the next stage of cannabis legalization—a step that will keep A the country firmly at the vanguard of a societal revolution and a new industry exploding with potential. “Cannabis 2.0” will see edibles containing cannabis and cannabis concentrates become legal on October 17, 2019. Their legalization will mean seven classes of cannabis products will be approved for sale in Canada, as dried cannabis, cannabis oil, fresh cannabis, cannabis plants, cannabis plant seeds, were legalized in 2018. The speed with which Canada’s cannabis industry has evolved over the past 18 months has been truly remarkable. In this, our third annual report on Canada’s cannabis industry, Deloitte has taken a broader approach in our research. As in previous years, we conducted comprehensive market research to understand Canadian consumer sentiment on cannabis edibles and other alternative products coming with Cannabis 2.0 legalization. The introduction of these new products is creating new opportunities in product mixes, reaching new cannabis consumers not fully comfortable with traditional consumption methods currently available. 1 Nurturing new growth | Canada gets ready for Cannabis 2.0 | Introduction As well, we explore trends and Our research suggests that the new However, we do need to acknowledge issues affecting the cannabis sector, alternative cannabis products becoming that Canada’s legal recreational drawing on extensive interviews and legal in late 2019 will be a significant cannabis industry is still in its infancy.
    [Show full text]
  • Cannabis and Its Secondary Metabolites: Their Use As Therapeutic Drugs, Toxicological Aspects, and Analytical Determination
    medicines Review Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination Joana Gonçalves 1,†, Tiago Rosado 1,†, Sofia Soares 1,†, Ana Y. Simão 1,†,Débora Caramelo 1,†, Ângelo Luís 1,† , Nicolás Fernández 2,†,Mário Barroso 3, Eugenia Gallardo 1 and Ana Paula Duarte 1,* 1 Centro de Investigação em Ciências da Saúde, Faculdade de Ciências da Saúde da Universidade da Beira Interior (CICS-UBI), 6200-506 Covilhã, Portugal; [email protected] (J.G.); [email protected] (T.R.); sofi[email protected] (S.S.); [email protected] (A.Y.S.); [email protected] (D.C.); afl[email protected] (Â.L.); [email protected] (E.G.) 2 Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA). Junín 956 7mo piso. Ciudad Autónoma de Buenos Aires (CABA), Buenos Aires C1113AAD, Argentina; [email protected] 3 Serviço de Química e Toxicologia Forenses, Instituto de Medicina Legal e Ciências Forenses - Delegação do Sul, 1169-201 Lisboa, Portugal; [email protected] * Correspondence: [email protected]; Tel.: +35-127-532-9002 † These authors contributed equally to this work. Received: 31 January 2019; Accepted: 18 February 2019; Published: 23 February 2019 Abstract: Although the medicinal properties of Cannabis species have been known for centuries, the interest on its main active secondary metabolites as therapeutic alternatives for several pathologies has grown in recent years. This potential use has been a revolution worldwide concerning public health, production, use and sale of cannabis, and has led inclusively to legislation changes in some countries.
    [Show full text]
  • CREW Cannabis E-Use
    CANNABIS INFORMATION GUIDE ON USE, EFFECTS, SAFETY AND HELP V1.0 9/20 INTRODUCTION Cannabis is the most commonly used controlled Laws controlling the use of cannabis emerged drug in the UK. It is a plant that contains hundreds as early as the 14th century. The way that of different compounds called cannabinoids. The cannabis is legally controlled varies around the main psychoactive cannabinoid is called THC world. Some countries enforce strict laws that (tetrahydrocannabinol). Other cannabinoids in prohibit the minor possession of cannabis, some the cannabis plant include CBD (cannabidiol), provide cannabis for medicinal use, and others CBG (cannabigerol) and CBN (cannabinol). offer cannabis for sale to the public to use Plants are grown to contain different cannabinoid recreationally, in a similar way to the sale of concentrations and can therefore produce alcohol. different effects. All drug use has risks. This booklet is for inform- Cannabis plants have been a part of human history ation only and does not constitute or replace for thousands of years. The plant material can be medical advice. If you have medical concerns used for rope and fibres in addition to being used about your drug use, please speak to a medical for medicinal, psychoactive and religious professional. purposes. 02 GETTING HIGH? Before taking any drug… Spend at least two hours researching the drug you are planning to take. These sites contain more information about the risks and effects of different drugs: crew.scot drugsand.me psychonautwiki.org erowid.org tripsit.me l Test the drug. If you don't have access to a drug checking service, reagent testing kits are available online and can give a greater under- standing of what the drug contains, but they may not be suitable for identifying newer compounds or adulterants and can tell you nothing about purity or strength.
    [Show full text]
  • Multiresidue Analysis of Pesticides in Cannabis-Infused Edibles Extraction and Enhanced Matrix Removal Lipid Cleanup
    1 2 Joan Stevens , and Sue D’Antonio ; AOAC 2017 Multiresidue Analysis of Pesticides in Cannabis-Infused Edibles by 1 Agilent Technologies, Inc., 2850 Centerville Road, Wilmington, DE 19808, USA P-W-026 Extraction and Enhanced Matrix Removal-Lipid Cleanup 2 Agilent Technologies, Inc., 1834 TX-71, Cedar Creek, TX 78612, USA Introduction Experimental Results and Discussion Results and Discussion A cannabis edible, also called cannabis-infused food, is a food product that contains cannabinoids, New EMR-Lipid Formulation Cleanup: High Lipid Chocolate Chip Cannabis Cookies especially THC and CBD. Cannabis edibles are Cannabis-Infused Products EMR sorbent technology effectively traps lipids consumed for both medical and recreational To 2 mL of the ACN extract 0.5 mL of water is added, through two mechanisms: vortexed. C Figure 2 is a picture of the purposes. ➢ Size exclusion – Unbranched hydrocarbon chains The extract is passed through a new EMR-Lipid (lipids) enter the sorbent; bulky analytes do not. extracts. Photo A. after ACN Because cannabinoids are soluble formulation cartridge, 300 mg/3 mL by gravity, pull extraction of the cookie in lipids and alcohols, cannabis must be mixed with ➢ Sorbent chemistry – Lipid chains that enter the material (left), after cleanup d- vacuum at end to evacuate the cartridge. A B SPE (C18/PSA) (middle) or new one of these two substances in order to infuse the The eluted extract is analyzed by LC/MS/MS. sorbent are trapped by hydrophobic interactions. cannabinoids into the food. The oil-solubility of EMR-Lipid formulation cleanup Cascadia Herbal Tincture (right). A yellow color is still cannabis extracts has been known since ancient LC-MS/MS Instrument Conditions times.
    [Show full text]
  • The Official High Times Cannabis Cookbook: More Than 50 Irresistible Recipes That Will Get You High
    CONTENTS ACKNOWLEDGMENTS INTRODUCTION TO CANNABIS COOKERY CHAPTER 1: Active Ingredients Basic Recipes THC Oil (Cannabis-Infused Oil) Cannacoconut Oil Cannabis-Infused Mayonnaise Simple Cannabutter Long-Simmering Cannabutter Wamm Marijuana Flour Tinctures Quick Cannabis Glycerite Long-Simmering Ganja Glycerin Green Avenger Cannabis Tincture CHAPTER 2: Irie Appetizers Roasted Ganja Garlic Cannellini Dip Hookah Lounge Hummus Green Leafy Kale Salad in Brown Cannabutter Vinaigrette Obama’S Sativa Samosas Stuffed Stoned JalapeñO Poppers Sativa Shrimp Spring Rolls with Mango Sauce Ganja Guacamole Mini Kind Veggie Burritos Pico de Ganja and Nachos Kind Bud Bruschetta with Pot Pesto Stoner Celebrity Favorite: Lil’ Snoop Hot Doggy Doggs CHAPTER 3: Munchie Meals Reggae Rice and Bean Soup Cream of Sinsemilla Soup Tom Yum Ganja Stoner Celebrity Favorite: Texas Cannabis Chili Shroomin’ Broccoli Casserole Om Circle Stuffed Butternut Squash Chicken and Andouille Ganja Gumbo Time-Warp Tamales Red, Green, and Gold Rasta Pasta Potato Gnocchi with Wild Mushroom Ragu Big Easy Eggplant Alfredo Ganja Granny’s Smoked Mac ‘n’ Cheese Psychedelic Spanakopita Sour Diesel Pot Pie Cheeto Fried Chicken Bacon-Wrapped Pork Tenderloin with Mango Chipotle Glaze Pot-and-Pancetta-Stuffed Beef Tenderloin with Port Mushrooms CHAPTER 4: High Holidays Valentine’s Day, February 14: Sexy Ganja–Dipped Strawberries St. Patrick’s Day, March 17: Green Ganja Garlic Smashed Potatoes 4/20, Cannabis Day, April 20: 420 Farmers’ Market Risotto Independence Day, July 4: Sweet and Tangy Bar–B–Cannabis
    [Show full text]
  • Cannabis Edibles, Cannabis Topicals and Cannabis Concentrates Will Be Legally Produced for Recreational Use and Sold to Adults in Canada As of October 17, 2019
    CANNABIS PRODUCTS, INCLUDING EDIBLES Drug Free Kids Canada Where families come for help This year, a variety of cannabis products for recreational use* will be entering the retail market. Cannabis edibles, cannabis topicals and cannabis concentrates will be legally produced for recreational use and sold to adults in Canada as of October 17, 2019. Only licensed cannabis producers will be able to develop these products for legal sale. These products will be available for purchase in stores and online. Chances are that your kids may have already heard about cannabis edibles, topicals and concentrates on the news, social media or from their friends or other adults. Cannabis and a variety of cannabis products like edibles and oils have been around for decades, most of them homemade. It’s normal that young people may be curious about the legalisation of these new cannabis products, and it’s important to keep in mind that curiosity doesn’t necessarily lead to experimentation. Being informed about these cannabis products will help you understand exactly what they are, how they are consumed and the potential impact their use could have on youth. As parents, you are one of the most powerful influences in your child’s life, and having thoughtful and well-informed conversations about cannabis with your pre-teen or teen can help them make informed and healthy choices. We are here to help. Youth and Cannabis Use in Canada: A recent study in Canada shows that 17% or nearly one in five students in grades 7 through 12 reported using cannabis products between October 2016 and June 2017.
    [Show full text]
  • Weed Tourism Is Heading to Atlantic City. It May Not Be What You Expect
    Weed tourism is heading to Atlantic City. It may not be what you expect. BILL BARLOW For The Press ATLANTIC CITY — Years later than promised, Gov. Phil Murphy on Monday signed three bills bringing legal weed to New Jersey. A little later in the week, about 100 people attended a virtual event to hear about ways in which legal cannabis can be a boon to the gaming, hospitality and tourism industries, and how preparation should begin now. Most experts say it will still be at least another year before the first taxed and legal sales take place in New Jersey, aside from the already-established medicinal market. Once it gets rolling, adult-use sales are expected to be worth billions statewide. Some of those sales will almost certainly be to out-of-state visitors, as the new market draws people from New York, Philadelphia and beyond to Jersey dispensaries. If you’re picturing a smoky, raucous tour bus loaded with stoned tourists, you may want to think again. Smoking is the least popular means of ingesting cannabis, and cannabis-motivated travelers have little interest in party buses, participants in a virtual conference on marijuana and tourism heard Wednesday. Instead, those attending “Destination Cannabis: Insight for New Jersey Hospitality and Tourism” heard about gourmet infusions combining seasonal ingredients and marijuana and about a thirst for education and cultural experiences. The virtual event was presented by the Lloyd D. Levenson Institute of Gaming, Hospitality and Tourism at Stockton University in partnership with the Greater Atlantic City Chamber and Stockton University Cannabis Studies program.
    [Show full text]
  • Report 4 of the Council on Science and Public Health
    REPORT 4 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (November 2020) (Resolutions 408-A-19, 411-A-19 and Alternate Resolution 913-I-19) Public Health Impacts of Cannabis Legalization (Reference Committee E) EXECUTIVE SUMMARY Objective. To review developments in cannabinoid pharmacology, update relevant sections of Council Report 5-I-17, “Clinical Implications and Policy Considerations of Cannabis Use,” and evaluate the public health impacts in states that have legalized cannabis for adult use to determine whether modifications to AMA are warranted. Methods. English language reports were selected from searches of the PubMed, Google Scholar, and Cochrane Library databases from August 2017 to August 2020 using the (text or MeSh) search terms “marijuana or cannabis or cannabinoid or cannabidiol” in combination with “legalization or laws,” and “health,” “mental or public health,” “addiction or cannabis use disorder,” “health effects,” “use,” “benefits or harms,” “youth or adolescents,” “edibles,” “driving,” “taxes,” “social equity or justice” and “treatment.” Additional articles were identified through related article searches and by manual review of the reference lists of retrieved articles. Websites managed by federal and state agencies, and applicable regulatory and advocacy organizations also were consulted for relevant information. Results. Thirty-three states have legalized medicinal use of cannabis. Eleven of these states have legalized cannabis for adult use. All 17 states that have not legalized medical use of cannabis allow the use of cannabidiol (CBD) in some way, as does the federal government for CBD products derived from hemp containing ≤0.3% Δ-9-tetrahydrocannabinol (THC). The health effects of cannabis and cannabinoids described in Council Report 5-I-17 remain valid; additionally, attention has been drawn to increased cardiovascular risks with cannabis use.
    [Show full text]
  • Cannabis Capitalism in Colorado: an Ethnography of Il/Legal Production and Consumption
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School April 2021 Cannabis Capitalism in Colorado: An Ethnography of Il/legal Production and Consumption Lia Berman University of South Florida Follow this and additional works at: https://scholarcommons.usf.edu/etd Part of the Economics Commons, Political Science Commons, and the Social and Cultural Anthropology Commons Scholar Commons Citation Berman, Lia, "Cannabis Capitalism in Colorado: An Ethnography of Il/legal Production and Consumption" (2021). Graduate Theses and Dissertations. https://scholarcommons.usf.edu/etd/8735 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Cannabis Capitalism in Colorado: An Ethnography of Il/legal Production and Consumption by Lia Berman A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Anthropology College of Arts and Sciences University of South Florida Major Professor: Kevin A. Yelvington, D.Phil. Anand Kumar, Ph.D. Marty Otañez, Ph.D. E. Christian Wells, Ph.D. Rebecca K. Zarger, Ph.D. Date of Approval: April 1, 2021 Keywords: Economic Anthropology, Political Economy, Commodity Chain, Budtender Copyright © 2021, Lia Berman ACKNOWLEDGMENTS I would like to first say a very big thank you to my supervisor, Dr. Kevin Yelvington, who provided guidance through each stage of the dissertation process. Without his patience and feedback, this Ph.D. would not have been achievable. Special thanks to Bárbara Cruz-Yelvington, who provided outstanding hospitality and comfort that will never be forgotten.
    [Show full text]
  • ADOPTED REGULATION of the DIVISION of PUBLIC and BEHAVIORAL HEALTH of the DEPARTMENT of HEALTH and HUMAN SERVICES LCB File No. R
    ADOPTED REGULATION OF THE DIVISION OF PUBLIC AND BEHAVIORAL HEALTH OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES LCB File No. R148-15 Effective September 9, 2016 EXPLANATION – Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY: §§1-15, 21-27 and 29-73, NRS 453A.370; §16, NRS 453A.210, 453A.370 and 453A.740; §§17-19, NRS 453A.370 and 453A.740; §20, NRS 453A.740; §§28 and 74, NRS 453A.344 and 453A.370. A REGULATION relating to the medical use of marijuana; establishing provisions relating to the use of concentrated cannabis by a medical marijuana establishment; revising provisions relating to the sale of marijuana and related products by a medical marijuana establishment to a person who holds a letter of approval or his or her designated primary caregiver; revising provisions relating to the cultivation, production, handling and labeling of marijuana and related products by a medical marijuana establishment; revising various provisions relating to the licensing and operation of a medical marijuana establishment and medical marijuana establishment agent; authorizing certain activities for research and development purposes by certain medical marijuana establishments; and providing other matters properly relating thereto. Legislative Counsel’s Digest: Existing law provides a limited exemption from state prosecution for certain crimes relating to marijuana for a person who holds a valid registry identification card. (NRS 453A.200) The Nevada Legislature provided for the creation of a letter of approval that grants a similar limited exemption to certain persons under 10 years of age. (Section 13 of Senate Bill No.
    [Show full text]